Építés alatt – nem éles oldal
Belépés
Fut, nem toboroz4. fázis

Tapering of biologics in chronic rhinosinusitis with nasal polyps

A legfontosabb adatok

Ki végzi
Rigshospitalet
Hol
Dánia9 helyszín, 1 országbanVálassz országot a helyszínekhez
Állapot
Fut, nem toboroz
Fázis
4. fázis
Résztvevők
135 fő, tervezett
Kezdés
2025. máj. 27.
Várható befejezés
2028. márc. 1.
A vizsgálat típusa
Beavatkozással járó
A regiszteradat frissítve
2025. november 12.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • ≥18 years of age. • Currently receiving treatment with either Dupilumab (300 mg) or Mepolizumab (100 mg) every four weeks. • Having received the biologic at unchanged dosing interval for at least three months. • For at least 1 year during treatment with biologics, the patients’ CRSwNP must be categorized as either "controlled" as defined by presence of none of the following 7 items, or as “partly controlled” as defined by presence of 1-2 of the following 7 items (see EPOS 2020 table in protocol): 1. Nasal blockage: present on most days of the week 2. Rhinorrhoea/postnasal drip: mucopurulent on most days of the week 3. Facial pain/pressure1: present on most days of the week 4. Sense of smell: impaired 5. Sleep disturbance or fatigue1: present 6. Nasal endoscopy: diseased mucosa 7. Rescue treatment (systemic corticosteroids, ESS, antibiotics): need of 1 course of rescue treatment

Ki nem vehet részt

  • Patients with no or limited response to biologics (“uncontrolled” in EPOS table in the protocol) • Patients with a cancer diagnosis deemed by the investigator to preclude participation in the trial • Patients who, because of language barriers, are not able to understand Danish written information and, thus, are not able to answer questionnaires • Patients who currently receive biologics for any other disease (asthma not included) • Patients who are not able to give informed consent (i.e., patients who are permanently incapable) • Patients who are not eligible because of the investigator’s judgement • Patients who experience pregnancy during the study will be excluded after an unscheduled visit – active IVF treatment (please see the protocol) • Unwillingness to follow the study procedure

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The objective is to evaluate the impact of prolonged dosing intervals of biologic therapy in patients with CRSwNP who have demonstrated stable, completely or partly controlled disease. Specifically, the study will assess at least continued degree of disease control after 52 weeks of prolonged dosing intervals in patients who have received treatment with Mepolizumab or Dupilumab for at least 18 months, with consistent completely or partly controlled disease for a minimum of 12 months. The primary outcome is to find the percentage of patients achieving at least sustained degree of disease controll after tapering of biologics for CRSwNP. This will be evaluated by comparison of disease control assessments at weeks 0 and 52.

Adatok és források

Regiszteradat
Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
English Title: Tapering of biologics in CRSwNP Subtitle: Tapering of Mepolizumab or Dupilumab after 12 months of complete or partial disease control in patients with severe chronic rhinosinusitis with nasal polyposis – a national Danish RCT.
A regiszteradat frissítve
2025. november 12.